FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 890 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 Hero Nanny Permanently Injured While Saving 2-Year-Old From Speeding Car About... March 5, 2019 Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 April 6, 2022 Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 Load more HOT NEWS News digest – naked mole-rats, junk food deals, ovarian cancer drug... New on NCI’s Websites for August 2024 Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children How to Cope With Panic Attacks During Cancer
